Effectiveness of BNT162b2 and mRNA-1273 Second Doses and Boosters for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and SARS-CoV-2-Related Hospitalizations: A Statewide Report From the Minnesota Electronic Health Record Consortium

Paul E. Drawz, Malini DeSilva, Peter Bodurtha, Gabriela Vazquez Benitez, Anne Murray, Alanna M. Chamberlain, R. Adams Dudley, Stephen Waring, Anupam B. Kharbanda, Daniel Murphy, Miriam Halstead Muscoplat, Victor Melendez, Karen L. Margolis, Lynn McFarling, Roxana Lupu, Tyler N.A. Winkelman, Steven G. Johnson

Research output: Contribution to journalArticlepeer-review

Abstract

Using vaccine data combined with electronic health records, we report that mRNA boosters provide greater protection than a 2-dose regimen against SARS-CoV-2 infection and related hospitalizations. The benefit of a booster was more evident in the elderly and those with comorbidities.

Original languageEnglish (US)
Pages (from-to)890-892
Number of pages3
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume75
Issue number5
DOIs
StatePublished - Sep 14 2022

Keywords

  • COVID-19
  • SARS-CoV-2
  • booster
  • hospitalization
  • vaccine

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Effectiveness of BNT162b2 and mRNA-1273 Second Doses and Boosters for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and SARS-CoV-2-Related Hospitalizations: A Statewide Report From the Minnesota Electronic Health Record Consortium'. Together they form a unique fingerprint.

Cite this